Agios Pharmaceuticals, Inc. (AGIO) fundamentals score
Agios Pharmaceuticals is a commercial-stage biopharmaceutical company dedicated to redefining the future of rare disease treatment. Fueled by connections, it builds trusted partnerships with communities, collaborating to develop and deliver innovative medicines with the potential to transform lives.
Pharmaceutical Preparations · Healthcare · Listed on NASDAQ
Overall: 6.2 out of 10, Mixed fundamentals
- Growth: 7.0/10
- Profitability: 3.4/10
- Financial health: 7.9/10
- Earnings quality: 6.8/10
- Valuation: 6.7/10
Scores are calculated from Agios Pharmaceuticals, Inc.’s SEC filings, using the 12 months through 2026-06. Compare it with past big winners, check its flags, and see today’s price against its fundamentals in the full scorecard.
Other Healthcare stocks
- Nurix Therapeutics, Inc. (NRIX): 9.0/10
- Caredx, Inc. (CDNA): 8.9/10
- Dexcom, Inc. (DXCM): 8.8/10
- Exelixis Inc. (EXEL): 8.8/10
- Neurocrine Biosciences Inc. (NBIX): 8.7/10
- Progyny, Inc. (PGNY): 8.6/10
- Healthcare Services Group, Inc. (HCSG): 8.5/10
- Insulet Corporation (PODD): 8.5/10